AROI-ESTRO GYN Teaching Course

INTERTECC Preliminary Data: Jan 2015

All (N=61)

Treated within 60 days, n (%)

57 (93%) 50 (82%) 55 (90%) 45 (74%) 57 (93%) 30 (43%) 15 (21%) 15 (21%)

Completed 5 cycles cisplatin, n (%)

Achieved Hard Bowel Constraint (V45<250cc), n (%) Achieved Soft Bowel Constraint (V45<200cc), n (%)

Achieved Bone Marrow Constraints (V10<90%, V20<75%), n (%)

Active Bone Marrow Sparing, n (%)

FDG-PET, n (%) FLT-PET, n (%)

Bowel V45 (cc) (mean, s.d.)

147 ± 89

Bone Marrow V10 (mean, s.d.)

84% ± 6.3%

Bone Marrow V20 (mean, s.d.)

65% ± 9.8%

Bone Marrow V30 (mean, s.d.) Bone Marrow V40 (mean, s.d.)

42% ± 6.8% 19% ± 5.4% 26.0 ± 2.3 26.0 ± 2.6

Bone Marrow Mean Dose (Gy) (mean, s.d.) Active Bone Marrow Mean Dose (Gy) (mean, s.d.)

Completed both baseline & Follow-up QOL Assessment, n (%)

54 (89%) Courtesy: Loren Mell UCSD; PI INTERTECC